EF Hutton Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Can Fite Biofarma (AMEX:CANF) and maintained a price target of $10.
October 10, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Can Fite Biofarma and maintained a price target of $10, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $10 price target by EF Hutton suggests positive sentiment and confidence in Can Fite Biofarma's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100